A Study of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis (ROSE)

A Randomized, Double-blind, Parallel-group Study to Evaluate the Safety and Efficacy of Tocilizumab (TCZ) Versus Placebo in Combination With Disease Modifying Antirheumatic Drugs (DMARDs) in Patients With Moderate to Severe Active Rheumatoid Arthritis (RA)

This 2-arm study assessed the safety and efficacy of tocilizumab versus placebo, both in combination with disease modifying antirheumatic drugs (DMARDs), in regard to reduction in signs and symptoms, in patients with moderate to severe active rheumatoid arthritis with an inadequate response to DMARDs. Patients were randomized in a ratio of 2:1 to receive either tocilizumab 8 mg/kg intravenously (IV) or placebo IV every 4 weeks. All patients also received stable antirheumatic therapy, including permitted DMARDs. The anticipated time on study treatment was 3-12 months and the target sample size was 500+ individuals.

Study Overview

• Status: Completed
• Conditions: Rheumatoid Arthritis
• Intervention / Treatment: Drug: Tocilizumab; Drug: Permitted DMARDs; Drug: Placebo

• Study Type: Interventional
• Enrollment (Actual): 619
• Phase: Phase 3

Contacts and Locations

Study Locations

• Puerto Rico
  • San Juan, Puerto Rico, 00918
• United States
  • Alabama
    • Birmingham, Alabama, United States, 35205
    • Birmingham, Alabama, United States, 35215
    • Birmingham, Alabama, United States, 35294-7201
    • Montgomery, Alabama, United States, 36111
  • Arizona
    • Lake Havasu City, Arizona, United States, 86403
    • Paradise Valley, Arizona, United States, 85253
    • Peoria, Arizona, United States, 85381
    • Scottsdale, Arizona, United States, 85258
    • Scottsdale, Arizona, United States, 85251
  • Arkansas
    • Jonesboro, Arkansas, United States, 72401
  • California
    • Beverly Hills, California, United States, 90211
    • Escondido, California, United States, 92025
    • La Jolla, California, United States, 92037
    • Long Beach, California, United States, 90815
    • Los Angeles, California, United States, 90095
    • Pasadena, California, United States, 91107
    • Santa Maria, California, United States, 93454
    • Santa Monica, California, United States, 90404
    • Upland, California, United States, 91786
    • Van Nuys, California, United States, 91405
    • Walnut Creek, California, United States, 94598
    • Whittier, California, United States, 90606
  • Colorado
    • Colorado Springs, Colorado, United States, 80910
  • Connecticut
    • Trumbull, Connecticut, United States, 06611
  • District of Columbia
    • Washington, District of Columbia, United States, 20006
  • Florida
    • Dunedin, Florida, United States, 34698
    • Fort Lauderdale, Florida, United States, 33334
    • Lake Mary, Florida, United States, 32746
    • Melbourne, Florida, United States, 32901
    • Miami, Florida, United States, 33133
    • Ocala, Florida, United States, 34474
    • Orange Park, Florida, United States, 32073
    • Orlando, Florida, United States, 32804
    • Palm Harbor, Florida, United States, 34684
    • Plantation, Florida, United States, 33317
    • Sarasota, Florida, United States, 34239
    • Tamarac, Florida, United States, 33321
    • Tampa, Florida, United States, 33609
  • Georgia
    • Atlanta, Georgia, United States, 30342
    • Blue Ridge, Georgia, United States, 30513
    • Fort Valley, Georgia, United States, 31030
    • Tifton, Georgia, United States, 311794
  • Idaho
    • Boise, Idaho, United States, 83702
    • Idaho Falls, Idaho, United States, 83404
    • Nampa, Idaho, United States, 83687
  • Illinois
    • Downers Grove, Illinois, United States, 60515
    • Springfield, Illinois, United States, 62704
  • Indiana
    • Evansville, Indiana, United States, 47714
    • Munster, Indiana, United States, 46321
    • South Bend, Indiana, United States, 46601
  • Kansas
    • Leawood, Kansas, United States, 66209
  • Kentucky
    • Bowling Green, Kentucky, United States, 42102
    • Lexington, Kentucky, United States, 40515
  • Louisiana
    • Baton Rouge, Louisiana, United States, 70808
    • Baton Rouge, Louisiana, United States, 70810
    • Monroe, Louisiana, United States, 71203
    • New Orleans, Louisiana, United States, 70112
  • Maryland
    • Wheaton, Maryland, United States, 20902
  • Massachusetts
    • Mansfield, Massachusetts, United States, 02048
    • Worcester, Massachusetts, United States, 01610
    • Worcester, Massachusetts, United States, 01605
  • Michigan
    • Kalamazoo, Michigan, United States, 49009
    • St Clair Shores, Michigan, United States, 48080
  • Minnesota
    • Eagan, Minnesota, United States, 55121
  • Mississippi
    • Flowood, Mississippi, United States, 39232
    • Tupelo, Mississippi, United States, 38802
  • Missouri
    • Florissant, Missouri, United States, 63031
    • St Louis, Missouri, United States, 63141
  • Montana
    • Billings, Montana, United States, 59101
    • Kalispell, Montana, United States, 59907
    • Missoula, Montana, United States, 59802
  • Nebraska
    • Grand Island, Nebraska, United States, 68803
  • Nevada
    • Las Vegas, Nevada, United States, 89128
    • Las Vegas, Nevada, United States, 89106
    • Reno, Nevada, United States, 89502
  • New Hampshire
    • Dover, New Hampshire, United States, 03820
  • New Jersey
    • Freehold, New Jersey, United States, 07728
    • New Brunswick, New Jersey, United States, 08903
    • Passaic, New Jersey, United States, 07055
    • Teaneck, New Jersey, United States, 07666
  • New York
    • Bronx, New York, United States, 10451
    • Mineola, New York, United States, 11501
    • New York, New York, United States, 10029
    • New York, New York, United States, 10003
    • Orchard Park, New York, United States, 14127
    • Smithtown, New York, United States, 11787
  • North Carolina
    • Belmont, North Carolina, United States, 28012
    • Charlotte, North Carolina, United States, 28210
    • Charlotte, North Carolina, United States, 28209
    • Durham, North Carolina, United States, 27704
    • Greensboro, North Carolina, United States, 27408
    • Greenville, North Carolina, United States, 27834
    • Hickory, North Carolina, United States, 28601
    • Rock Hill, North Carolina, United States, 29732
  • Ohio
    • Akron, Ohio, United States, 44333
    • Beechwood, Ohio, United States, 44122
    • Mayfield, Ohio, United States, 44143
    • Middleburg Heights, Ohio, United States, 44130
    • Perrysburg, Ohio, United States, 43551
    • Zanesville, Ohio, United States, 43701
  • Oklahoma
    • Norman, Oklahoma, United States, 73069
    • Oklahoma City, Oklahoma, United States, 73104
    • Oklahoma City, Oklahoma, United States, 73103
  • Oregon
    • Lake Oswego, Oregon, United States, 97035
    • Portland, Oregon, United States, 97239
    • Salem, Oregon, United States, 97302
  • Pennsylvania
    • Bethlehem, Pennsylvania, United States, 10817
    • Philadelphia, Pennsylvania, United States, 19152
    • Philadelphia, Pennsylvania, United States, 19102
    • Pittsburgh, Pennsylvania, United States, 15261
    • Wexford, Pennsylvania, United States, 15090
    • Willow Grove, Pennsylvania, United States, 80045
  • South Carolina
    • Charleston, South Carolina, United States, 29407
    • Columbia, South Carolina, United States, 29204
    • Florence, South Carolina, United States, 29506
    • Greenville, South Carolina, United States, 29601
    • Myrtle Beach, South Carolina, United States, 29572
  • South Dakota
    • Rapid City, South Dakota, United States, 57702
    • Rapid City, South Dakota, United States, 57701
    • Sioux Falls, South Dakota, United States, 57105
    • Watertown, South Dakota, United States, 57201
  • Tennessee
    • Crossville, Tennessee, United States, 38555
    • Hendersonville, Tennessee, United States, 37073
    • Jackson, Tennessee, United States, 38305
    • Knoxville, Tennessee, United States, 37909
    • Memphis, Tennessee, United States, 38119
    • Nashville, Tennessee, United States, 37203
  • Texas
    • Amarillo, Texas, United States, 79106
    • Amarillo, Texas, United States, 79124
    • Bellaire, Texas, United States, 77401
    • Carrollton, Texas, United States, 75007
    • Dallas, Texas, United States, 75231
    • Fort Worth, Texas, United States, 76107
    • Houston, Texas, United States, 77004
    • Houston, Texas, United States, 77034
    • Houston, Texas, United States, 77074
    • Houston, Texas, United States, 77090
    • Mesquite, Texas, United States, 75150
    • San Antonio, Texas, United States, 78229
    • San Antonio, Texas, United States, 78217
    • San Antonio, Texas, United States, 78258
    • Temple, Texas, United States, 76508
    • Waco, Texas, United States, 76708
  • Utah
    • Salt Lake City, Utah, United States, 84132
  • Vermont
    • Burlington, Vermont, United States, 05401
  • Virginia
    • Burke, Virginia, United States, 22015
    • Reston, Virginia, United States, 22102
    • Salem, Virginia, United States, 24153
  • Washington
    • Seattle, Washington, United States, 98133
    • Seattle, Washington, United States, 98195
    • Spokane, Washington, United States, 99204-2336
  • West Virginia
    • Beckley, West Virginia, United States, 25801
    • Clarksburg, West Virginia, United States, 26301
  • Wisconsin
    • Milwaukee, Wisconsin, United States, 53209
    • Onalaska, Wisconsin, United States, 54605
    • Wausau, Wisconsin, United States, 54401

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Adult patients, ≥18 years of age
• Active rheumatoid arthritis of >6 months duration
• Received permitted DMARDs each at a stable dose for at least 7 weeks prior to baseline

Exclusion Criteria:

• Rheumatic autoimmune disease or inflammatory joint disease other than rheumatoid arthritis
• Major surgery within 8 weeks prior to screening or planned within 6 months following randomization
• Unsuccessful treatment with a biologic agent, including an anti-TNF agent
• Previous treatment with tocilizumab

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Tocilizumab 8 mg/kg + DMARDs	Drug: Tocilizumab; Tocilizumab intravenously at a dose of 8 mg/kg over a 1-hour infusion, every 4 weeks, for a total of 6 infusions.; Other Names: RoActemra; Actemra; Drug: Permitted DMARDs; As prescribed. The following DMARDs were permitted in this study: methotrexate (MTX), chloroquine, hydroxychloroquine, parenteral gold, sulfasalazine, azathioprine, and leflunomide. These DMARDs could be used alone or in combination, except for the combination of MTX and leflunomide, which was not allowed.
Placebo Comparator: Placebo + DMARDs	Drug: Permitted DMARDs; As prescribed. The following DMARDs were permitted in this study: methotrexate (MTX), chloroquine, hydroxychloroquine, parenteral gold, sulfasalazine, azathioprine, and leflunomide. These DMARDs could be used alone or in combination, except for the combination of MTX and leflunomide, which was not allowed.; Drug: Placebo; Placebo IV over a 1-hour infusion, every 4 weeks, for a total of 6 infusions.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Patients With an Improvement of at Least 50% in American College of Rheumatology (ACR) Score (ACR50) From Baseline at Week 24	Improvement must be seen in tender and swollen joint counts and in at least 3 of the following 5 parameters. Patient and physician assessment of patient disease activity (DA) in previous 24 hours on a visual analog scale (VAS, no DA to maximum DA); patient assessment of pain in previous 24 hours on a VAS (none to unbearable); Health Assessment Questionnaire-Disability Index (20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do); and C-reactive protein or, if missing, erythrocyte sedimentation rate.	Baseline to Week 24

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Patients With an Improvement of at Least 20%, 50%, or 70% in American College of Rheumatology (ACR) Score (ACR20, ACR50, ACR70) From Baseline at Weeks 4, 8, 12, 16, 20, and 24	Improvement must be seen in tender and swollen joint counts and in at least 3 of the following 5 parameters. Patient and physician assessment of patient disease activity (DA) in previous 24 hours on a visual analog scale (VAS, no DA to maximum DA); patient assessment of pain in previous 24 hours on a VAS (none to unbearable); Health Assessment Questionnaire-Disability Index (20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do); and C reactive protein or, if missing, erythrocyte sedimentation rate.	Baseline to Weeks 4, 8, 12, 16, 20, 24
Mean Change From Baseline in Disease Activity Score 28 (DAS28) at Weeks 4, 8, 12, 16, 20, and 24	DAS28 was calculated using the following formula: 0.56 × sqrt(TJC) + 0.28 × sqrt(SJC) + 0.70 × ln(ESR) + 0.014 × GH, where TJC = tender joint count on 28 joints, SJC = swollen joint count on 28 joints, ESR = erythrocyte sedimentation rate at the current visit (mm/hr), and GH = general health, ie, the patient's global assessment of disease activity (DA) in the previous 24 hours on a 100 mm visual analog scale (no DA to maximum DA). The DAS28 score ranges from 0 to 10, with higher scores indicating more rheumatoid arthritis. A negative change score indicates improvement.	Baseline to Weeks 4, 8, 12, 16, 20, 24
Percentage of Patients With European League Against Rheumatism (EULAR) Good, Moderate, or no Response at Weeks 4, 8, 12, 16, 20, and 24	Change of the DAS28 score from baseline was used to determine the EULAR responses of good, moderate, or no response. For a post-baseline score ≤ 3.2, a change from baseline of < -1.2 was a good response, < -0.6 to ≥ -1.2 was a moderate response, and ≥ -0.6 was no response. For a post-baseline score > 3.2 to ≤ 5.1, a change from baseline of < -0.6 was a moderate response and ≥ -0.6 was no response. For a post-baseline score > 5.1, a change from baseline < -1.2 was a moderate response and ≥ -1.2 was no response. A good response could not be achieved for post-baseline scores > 3.2.	Baseline to Weeks 4, 8, 12, 16, 20, and 24
Mean Change From Baseline in the Routine Assessment Patient Index Data (RAPID) Score at Weeks 4, 8, 12, 16, 20, and 24	Derived from the Multidimensional Health Assessment Questionnaire (MDHAQ), the RAPID includes 3 domains that assess disease activity in rheumatoid arthritis: A physical function score (MDHAQ items 1a-j), a pain visual analog scale score (VAS, item 2 in the MDHAQ), and a global assessment of disease activity VAS score (item 6 in the MDHAQ). Each domain is scored on a scale of 0-10. The RAPID score is the sum of the 3 domain scores divided by 3 resulting in a total score on a scale of 0-10. Higher scores indicate more disease activity and a negative change from baseline indicates improvement.	Baseline to Weeks 4, 8, 12, 16, 20, and 24
Mean Change From Baseline in 12-Item Short Form Health Survey v2 (SF-12) Scores at Weeks 4, 8, 12, 16, 20, and 24	The SF-12 is a self-report measure of general health status with 1 or 2 items for each of 8 domains: Physical functioning, role limitations due to physical health problems, bodily pain, general health, vitality, social functioning, role limitations due to emotional problems, and mental health. Two component summaries, physical (PCS-12) and mental (MCS-12) were calculated using norm-based scoring, resulting in means of 50 and standard deviations of 10 in the 1998 general United States population. Higher scores represent better health and a positive change from baseline represents improvement.	Baseline to Weeks 4, 8, 12, 16, 20, and 24
Mean Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score at Weeks 4, 8, 12, 16, 20, and 24	The FACIT-F is a 13-item patient self-report questionnaire that assesses fatigue over the previous 7 days by scoring each item on a 5-point scale (0=Not at all, 1=A little bit, 2=Somewhat, 3=Quite a bit, 4=Very much). An overall FACIT-F score was obtained by summing the scores of all 13 items. The overall score ranged from 0 to 52. A lower score indicates less fatigue. A negative change score indicates improvement.	Baseline to Weeks 4, 8, 12, 16, 20, and 24
Mean Change From Baseline in the Medical Outcomes Study (MOS) Sleep Scale Score at Weeks 4, 8, 12, 16, 20, and 24	The MOS Sleep Scale is a 12-item patient self-report instrument that assesses the quality and quantity of sleep over the previous 4 weeks. A sleep problems index (SLP9) was generated using 9 of the 12 items (1, 3, 4, 5, 6, 7, 8, 9, 12). Each item was normalized so that the lowest and highest possible scores were set to 0 and 100, respectively. The SLP9 score is the average of the recoded 9 items. The SLP9 score ranged from 0 to 100. Higher scores represent greater sleep problems. A negative change score indicates improvement.	Baseline to Weeks 4, 8, 12, 16, 20, and 24
Mean Change From Baseline in Individual Components of the Routine Assessment Patient Index Data (RAPID) at Each Day During the First 7 Days of Treatment	Derived from the Multidimensional Health Assessment Questionnaire (MDHAQ), the RAPID includes 3 domains that assess disease activity in rheumatoid arthritis: A physical function score (0-10), a pain visual analog scale score (VAS, 0-100), and a global assessment of disease activity VAS score (0-100). Each domain was assessed with the Patient Take Home Form (PTHF). Higher scores indicate more disease activity. A negative change score indicates improvement.	Baseline through Day 7
Percentage of Patients With an Improvement of at Least 20%, 50%, or 70% in American College of Rheumatology (ACR) Score (ACR20, ACR50, ACR70) From Baseline at Day 7	Improvement must be seen in tender and swollen joint counts and in at least 3 of the following 5 parameters. Patient and physician assessment of patient disease activity (DA) in previous 24 hours on a visual analog scale (VAS, no DA to maximum DA); patient assessment of pain in previous 24 hours on a VAS (none to unbearable); Health Assessment Questionnaire-Disability Index (20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do); and C reactive protein or, if missing, erythrocyte sedimentation rate.	Baseline to Day 7
Mean Change From Baseline in C-reactive Protein (CRP) at Days 3 and 7	Serum concentration of CRP (high-sensitivity CRP [hsCRP] test) was analyzed by a central laboratory.	Baseline to Days 3 and 7

Collaborators and Investigators

• Sponsor: Hoffmann-La Roche

Publications and helpful links

General Publications

• Yazici Y, Curtis JR, Ince A, Baraf HS, Lepley DM, Devenport JN, Kavanaugh A. Early effects of tocilizumab in the treatment of moderate to severe active rheumatoid arthritis: a one-week sub-study of a randomised controlled trial (Rapid Onset and Systemic Efficacy [ROSE] Study). Clin Exp Rheumatol. 2013 May-Jun;31(3):358-64. Epub 2013 Jan 10.
• Yazici Y, Curtis JR, Ince A, Baraf H, Malamet RL, Teng LL, Kavanaugh A. Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study. Ann Rheum Dis. 2012 Feb;71(2):198-205. doi: 10.1136/ard.2010.148700. Epub 2011 Sep 26.

Helpful Links

• Clinical Study Report Synopsis

Study record dates

Study Major Dates

• Study Start: October 1, 2007
• Primary Completion (Actual): June 1, 2009
• Study Completion (Actual): March 1, 2011

Study Registration Dates

• First Submitted: September 18, 2007
• First Submitted That Met QC Criteria: September 18, 2007
• First Posted (Estimate): September 19, 2007

Study Record Updates

• Last Update Posted (Estimate): August 20, 2012
• Last Update Submitted That Met QC Criteria: August 13, 2012
• Last Verified: August 1, 2012

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Immune System Diseases; Autoimmune Diseases; Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Connective Tissue Diseases; Arthritis; Arthritis, Rheumatoid
• Other Study ID Numbers: ML21136